Terms: = Prostate cancer AND Ki-67 AND Staging
15 results:
1. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
Arslan E; Ergül N; Beyhan E; Erol Fenercioglu Ö; Sahin R; Cin M; Battal Havare S; Can Trabulus FD; Mermut Ö; Akbas S; Fikret Çermik T
Nucl Med Commun; 2023 Apr; 44(4):284-290. PubMed ID: 36756767
[TBL] [Abstract] [Full Text] [Related]
2. Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis.
Corrao G; Marvaso G; Zaffaroni M; Volpe S; Augugliaro M; Fodor CI; Zerini D; Vingiani A; Mistretta FA; Luzzago S; Alessi S; Pricolo P; Musi G; De Cobelli O; Renne G; Manzoni M; Petralia G; Orecchia R; Jereczek-Fossa BA
Neoplasma; 2022 Mar; 69(2):404-411. PubMed ID: 35014537
[TBL] [Abstract] [Full Text] [Related]
3. An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer.
Brönimann S; Pradere B; Karakiewicz P; Abufaraj M; Briganti A; Shariat SF
Expert Rev Mol Diagn; 2020 Aug; 20(8):841-850. PubMed ID: 32552088
[TBL] [Abstract] [Full Text] [Related]
4. Apoptotic and predictive factors by Bax, Caspases 3/9, Bcl-2, p53 and ki-67 in prostate cancer after 12 Gy single-dose.
Pisani C; Ramella M; Boldorini R; Loi G; Billia M; Boccafoschi F; Volpe A; Krengli M
Sci Rep; 2020 Apr; 10(1):7050. PubMed ID: 32341393
[TBL] [Abstract] [Full Text] [Related]
5. Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.
Li S; Wu Z; Chen Y; Kang Z; Wang H; He P; Zhang X; Hu T; Zhang Q; Cai Y; Xu X; Guan M
Tumour Biol; 2016 Apr; 37(4):5365-74. PubMed ID: 26561474
[TBL] [Abstract] [Full Text] [Related]
6. [Correlation of FOXA1 with the malignancy and progression of prostate cancer].
Feng W; Zhang HB; Wang YM; Hu JL
Zhonghua Nan Ke Xue; 2015 May; 21(5):414-9. PubMed ID: 26117938
[TBL] [Abstract] [Full Text] [Related]
7. Does ki-67 staining improve quantitative histology in preoperative prostate cancer staging?
Pepe P; Fraggetta F; Candiano G; Aragona F
Arch Ital Urol Androl; 2012 Mar; 84(1):32-5. PubMed ID: 22649958
[TBL] [Abstract] [Full Text] [Related]
8. The role of the intravascular microenvironment in spontaneous metastasis development.
Zhang Q; Yang M; Shen J; Gerhold LM; Hoffman RM; Xing HR
Int J Cancer; 2010 Jun; 126(11):2534-41. PubMed ID: 19847811
[TBL] [Abstract] [Full Text] [Related]
9. The expression of metallothioneins on imprint smears of prostate carcinoma: correlation with clinicopathologic parameters and tumor proliferative capacity.
Athanassiadou P; Bantis A; Gonidi M; Athanassiades P; Agelonidou E; Grapsa D; Nikolopoulou P; Patsouris E
Tumori; 2007; 93(2):189-94. PubMed ID: 17557567
[TBL] [Abstract] [Full Text] [Related]
10. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer.
Breeuwsma AJ; Pruim J; Jongen MM; Suurmeijer AJ; Vaalburg W; Nijman RJ; de Jong IJ
Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):668-73. PubMed ID: 15765234
[TBL] [Abstract] [Full Text] [Related]
11. Molecular markers in prostate cancer: the role in preoperative staging.
Moul JW; Merseburger AS; Srivastava S
Clin Prostate Cancer; 2002 Jun; 1(1):42-50. PubMed ID: 15046712
[TBL] [Abstract] [Full Text] [Related]
12. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy.
Moul JW; Kane CJ; Malkowicz SB
Urol Clin North Am; 2001 Aug; 28(3):459-72. PubMed ID: 11590806
[TBL] [Abstract] [Full Text] [Related]
13. Micrometastatic bone marrow involvement: detection and prognostic significance.
Braun S; Pantel K
Med Oncol; 1999 Sep; 16(3):154-65. PubMed ID: 10523795
[TBL] [Abstract] [Full Text] [Related]
14. Angiogenesis, p53, bcl-2 and ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract] [Full Text] [Related]
15. Accelerated tumor proliferation rates in locally recurrent prostate cancer after radical prostatectomy.
Connolly JA; Presti JC; Cher ML; Chew K; Shinohara K; Carroll PR
J Urol; 1997 Aug; 158(2):515-8. PubMed ID: 9224336
[TBL] [Abstract] [Full Text] [Related]
